Known targets — ChEMBL curated mechanism
GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.56 |
| ▸ | CA4 | P22748 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CPT2 | P23786 | 1/20 | 0.41 |
| ▸ | CPT1A | P50416 | 1/20 | 0.41 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21546042 | 0.95 | — | — | |
| Potassium Ion SCHEMBL30197149 | 0.95 | — | — | |
| SCHEMBL29635923 | 0.95 | SLC22A16 (0.56) | SLC22A16CA4CA2CPT2CPT1A | |
| Zinc Ion SCHEMBL28972722 | 0.95 | SLC22A16 (0.56) | SLC22A16CA4CA2CPT2CPT1A | |
| SCHEMBL28701377 | 0.95 | SLC22A16 (0.56) | SLC22A16CA4CA2CPT2CPT1A | |
| SCHEMBL31500043 | 0.95 | — | — | |
| SCHEMBL31500045 | 0.86 | SLC22A6 (0.50) | SLC22A16CA4CA2NFKB1GPR84 | |
| SCHEMBL29441846 | 0.81 | SLC22A6 (0.44) | SLC22A16CA4CA2GPR84 | |
| SCHEMBL10423091 | 0.77 | CA4 (0.60) | SLC22A16CA4CA2CPT2CPT1A | |
| Silver SCHEMBL6733932 | 0.77 | SLC22A16 (0.59) | SLC22A16CA4CA2CPT2CPT1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119968132-A | Acid and salt compound and preparation method thereof | 南京纽邦生物科技有限公司 | 2025-05-09 | — | — | CN | claimed |
| WO-2024067626-A1 | COMPOSITE OF ACID AND SALT, AND PREPARATION METHOD THEREFOR | 南京纽邦生物科技有限公司 | 2024-04-04 | — | — | WO | claimed |
| CN-119968132-A | Acid and salt compound and preparation method thereof | 南京纽邦生物科技有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-12167993-B2 | Non-vasoconstricting energy-promoting compositions containing ketone bodies | AXCESS GLOBAL SCIENCES, LLC (US) | 2024-12-17 | — | — | US | disclosed |
| US-20240293346-A1 | NON-VASOCONSTRICTING ENERGY-PROMOTING COMPOSITIONS CONTAINING KETONE BODIES | AXCESS GLOBAL SCIENCES, LLC | 2024-09-05 | — | — | US | disclosed |
| WO-2024067626-A1 | COMPOSITE OF ACID AND SALT, AND PREPARATION METHOD THEREFOR | 南京纽邦生物科技有限公司 | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12167993-B2 | Non-vasoconstricting energy-promoting compositions containing ketone bodies | GPR119, CPT1B, CYP11B1 | SLC22A16 705/4885CA4 1702/4885CA2 893/4885 |
| US-20240293346-A1 | NON-VASOCONSTRICTING ENERGY-PROMOTING COMPOSITIONS CONTAINING KETONE BODIES | GPR119, CPT1B, CYP11B1 | SLC22A16 705/4885CA4 1702/4885CA2 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.